Kodiak Sciences shares more than doubled Monday after the company said its Phase 3 study for Zenkuda and tabirafusp-ted met the primary endpoints for both drugs in patients with wet age-related macular degeneration.

The stock was 156% higher, at $82.80, in morning trade, its 52-week high.

The biotechnology company said the study demonstrated that both Zenkuda and tabirafusp-ted achieved non-inferiority in vision gains compared to aflibercept at year one.

Kodiak said Zenkuda demonstrated strong immediacy of clinical effect, matching and/or exceeding that of the aflibercept comparator through the loading phase. Zenkuda also demonstrated strong durability of clinical effect, with 54% of patients achieving 6-month durability at year one, while employing strict treat-to-dryness real world retreatment criteria.

Zenkuda and Tabirafusp-ted demonstrated favorable safety and were well tolerated.

Kodiak plans to submit the study data to regulatory authorities during the fourth quarter.